Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 27 articles:
HTML format



Single Articles


    August 2022
  1. KIM TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, et al
    First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:3452-3463.
    PubMed     Abstract available


  2. ZHU Z, Ma AH, Zhang H, Lin TY, et al
    Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer.
    Clin Cancer Res. 2022 Aug 3. pii: 707432. doi: 10.1158/1078-0432.CCR-22-1362.
    PubMed     Abstract available


    July 2022
  3. SZABADOS B, Ponz-Sarvis M, Machado R, Saldana D, et al
    Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).
    Clin Cancer Res. 2022 Jul 25. pii: 707208. doi: 10.1158/1078-0432.CCR-22-0200.
    PubMed     Abstract available


  4. PIETZAK EJ, Whiting K, Srinivasan P, Bandlamudi C, et al
    Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2022 Jul 14. pii: 707011. doi: 10.1158/1078-0432.CCR-22-1006.
    PubMed     Abstract available


    May 2022
  5. BELLMUNT J, de Wit R, Fradet Y, Climent MA, et al
    Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
    Clin Cancer Res. 2022;28:2050-2060.
    PubMed     Abstract available


    April 2022
  6. GIRARDI DM, Niglio SA, Mortazavi A, Nadal R, et al
    Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2022;28:1353-1362.
    PubMed     Abstract available


    February 2022
  7. SHENG X, Chen H, Hu B, Yao X, et al
    Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.
    Clin Cancer Res. 2022;28:489-497.
    PubMed     Abstract available


    September 2021
  8. WANG H, Mei Y, Luo C, Huang Q, et al
    Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-20-4796.
    PubMed     Abstract available


  9. CHU CE, Sjostrom M, Egusa EA, Gibb EA, et al
    Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
    Clin Cancer Res. 2021;27:5123-5130.
    PubMed     Abstract available


    August 2021
  10. WANG L, Sfakianos JP, Beaumont KG, Akturk G, et al
    Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
    Clin Cancer Res. 2021;27:4287-4300.
    PubMed     Abstract available


  11. WANG L, Sfakianos JP, Beaumont KG, Akturk G, et al
    Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
    Clin Cancer Res. 2021;27:4287-4300.
    PubMed     Abstract available


    July 2021
  12. TEO MY, Rosenberg JE
    NECTIN4 heterogeneity and molecular diversity in bladder cancers: deconstructing the activity of an antibody-drug conjugate.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1807.
    PubMed     Abstract available


  13. KOUTROS S, Rao N, Moore LE, Nickerson ML, et al
    Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
    Clin Cancer Res. 2021;27:3725-3733.
    PubMed     Abstract available


    June 2021
  14. DAMRAUER JS, Roell KR, Smith MA, Sun X, et al
    Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer.
    Clin Cancer Res. 2021 Jun 11. pii: 1078-0432.CCR-21-0205.
    PubMed     Abstract available


    May 2021
  15. DRAKE CG
    Myeloid Resistance is Not Futile: Biomarkers of Immunotherapy in Bladder Cancer.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1011.
    PubMed     Abstract available


  16. HASANALI SL, Morera DS, Racine RR, Hennig M, et al
    HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-21-0422.
    PubMed     Abstract available


  17. BORCSOK J, Diossy M, Sztupinszki Z, Prosz A, et al
    Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-5037.
    PubMed     Abstract available


    April 2021
  18. BORCSOK J, Sztupinszki Z, Bekele R, Gao SP, et al
    Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.
    Clin Cancer Res. 2021;27:2011-2022.
    PubMed     Abstract available


  19. CRABB SJ, Danson S, Catto JWF, Hussain S, et al
    Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
    Clin Cancer Res. 2021;27:1882-1892.
    PubMed     Abstract available


    February 2021
  20. CHANG E, Weinstock C, Zhang L, Charlab R, et al
    FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2021;27:922-927.
    PubMed     Abstract available


  21. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
    A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695).
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-2409.
    PubMed     Abstract available


    January 2021
  22. SHENG X, Yan X, Wang L, Shi Y, et al
    Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2021;27:43-51.
    PubMed     Abstract available


    February 2020
  23. LOKESHWAR VB, Morera DS, Hasanali SL, Yates TJ, et al
    A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Bladder Cancer Patients.
    Clin Cancer Res. 2020 Feb 24. pii: 1078-0432.CCR-19-2912.
    PubMed     Abstract available


  24. KOBATAKE K, Ikeda K, Nakata Y, Yamasaki N, et al
    Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction.
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-2230.
    PubMed     Abstract available


    January 2020
  25. SHARMA P, Sohn J, Shin SJ, Oh DY, et al
    Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.
    Clin Cancer Res. 2020;26:61-70.
    PubMed     Abstract available


    November 2019
  26. KATES M, Matoso A, Choi W, Baras AS, et al
    Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials.
    Clin Cancer Res. 2019 Nov 11. pii: 1078-0432.CCR-19-1920.
    PubMed     Abstract available


    February 2019
  27. GRIVAS P
    DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?
    Clin Cancer Res. 2019;25:907-909.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: